OXIMIO Canada Achieves Medical Device Establishment License (MDEL)
Oximio is pleased to announce that Oximio BARL Canada has officially obtained its Medical Device Establishment License (MDEL), effective December 2025. While BARL previously held an MDEL, this newly issued licence reflects our transition to operating under the Oximio Business Centre (OBC) structure and reinforces the continuity of our long-standing compliance.
Securing the updated MDEL formally authorizes Oximio to import, distribute, and store medical devices, further strengthening our service offering and expanding the range of solutions we can provide. The licence plays a vital role in ensuring the safety and quality of medical products in Canada by confirming that licence holders comply with rigorous regulatory requirements, including complaint handling, recall management, and incident reporting.
Kaitlin Guarasci, Managing Director of Oximio, Canada, commented on the achievement:
“This is a significant achievement as it further enhances our credibility, broadening the services we can provide to customers.”
This accomplishment reflects Oximio’s ongoing commitment to excellence, regulatory compliance, and delivering trusted solutions to the healthcare sector.
For further information on our supply chain solutions for clinical trials across Canada and North America, please visit our North America solutions page or contact us.
Oximio Kenya Secures Environmental Impact Assessment License from NEMA
Oximio is proud to announce that our Kenya Warehouse has officially received the Environmental Impact Assessment (EIA) License from the National Environment Management Authority (NEMA).
This is a significant milestone in our ongoing commitment to sustainable operations and environmental stewardship.
The EIA License serves as a comprehensive evaluation of how our warehouse activities interact with the environment, ensuring that we operate responsibly while balancing both economic growth and ecological protection.
Why the EIA License Is Important
- Legal Compliance: Confirms that Oximio operates in full accordance with Kenya’s environmental regulations.
- Environmental Protection: Demonstrates that our warehouse operations are designed and managed to safeguard surrounding ecosystems.
- Community Trust: Reinforces our dedication to transparency, safety, and sustainability, building lasting confidence among local communities.
We extend our thanks and congratulations to the Kenya Warehouse Management Team for achieving this important certification and for demonstrating Oximio’s dedication to creating a cleaner, greener, and more sustainable future.
Explore Oximio’s supply chain solutions for clinical trials in Kenya and contact us to find out how we can support your clinical research.
Oximio Türkiye Expands Cold Chain Capacity
We’re excited to share that Oximio Türkiye has recently completed the installation of a new 2–8°C cold room, which will become operational by the end of the year.
This investment increases our cold storage and handling capacity by more than 50%, ensuring we can continue to meet the needs of our growing operational activities and better support our clinical research partners.
Our new cold storage facility is fully compliant with Oximio standards and is designed to ensure the highest quality and integrity of investigational medicinal products and other temperature-sensitive materials used in clinical trials.
At Oximio, we remain committed to advancing our infrastructure to provide reliable, compliant, and scalable logistics solutions for clinical research across the region.
Find out more about how Oximio Türkiye can support your next clinical trial: https://oximio.com/network/turkiye/
Oximio to Open New Depot in Saudi Arabia
Building on our 20+ years reputation of providing reliable, tailormade, supply chain solutions for clinical trials across the globe, we’re excited to share that in Q1 2026, we will be strengthening our global network with the opening of a state-of-the-art depot in Saudi Arabia.
This new facility will offer core services including Importer of Record (IOR), storage, handling, and distribution, marking the beginning of our commitment to further support the region’s clinical trial needs. This expansion underlines our dedication to innovation and our commitment to providing a first-class service that’s synonymous with our outstanding reputation.
We look forward to developing strong partnerships with customers and working closely with regulatory authorities to deliver the exceptional service that has defined our reputation globally.
Stay tuned as we will be bringing you further updates in the coming weeks.
In the meantime, if you are running or planning a clinical trial within the region and would like further information on our facility and services, please contact us. We’d be delighted to discuss your requirements.
Strengthening Our Roots in the UK
Over the past months, Oximio has continued to strengthen its foundation in the United Kingdom – a region that plays a vital role in our global clinical trial supply chain.
A recent, successful, independent audit in the UK reaffirmed not only our financial health but also our commitment to transparency, compliance, and operational excellence.
Dr Zayheda Khan, Chief Commercial Officer & Managing Director (UK), said “Establishing solid roots in such a highly regulated and competitive environment allows us to better support clinical trials across Europe and beyond. It’s a reflection of the dedication of our teams, our partners’ trust, and our ongoing focus on doing things the right way – ethically, sustainably, and reliably”.
As we move forward, our focus remains clear: developing stronger relationships, and a resilient global foundation that enables scalable, future-ready clinical trial solutions.
Find out how we can support your clinical research in the UK and across Europe: https://oximio.com/network/uk/
Oximio Achieves Customs Agent License in Kenya, Enhancing Efficiency and Cost-Savings for Clients
Oximio is delighted to announce that it has obtained a Customs Agent License for its depot in Kenya, effective September 2025. This latest milestone means that Oximio can further enhance its services with greater operational control to clients across East Africa.
With this new license, Oximio now has the capability to manage its own import and export customs actions, eliminating the need for third-party involvement and giving the company full control over shipments.
The immediate benefits to clients are substantial. With the ability to pre-clear shipments before arrival, Oximio will significantly speed up the customs process, resulting in faster delivery times and increased operational efficiency. By streamlining processes and reducing costs, the new license will improve profitability for clients.
With fewer entities involved in customer shipments, this will help minimise delays and potential damage to their shipments.
Celeste de Vries, Regional Director of Sub-Saharan Africa, said “we are thrilled to have secured the Customs Agent License in Kenya, a significant achievement that marks a new chapter in our commitment to delivering exceptional service to our clients. This license gives us complete control over the customs process, ensuring faster, more reliable, and cost-effective solutions. It’s a win for our clients, our business, and the entire region. We’re proud to now be able to offer an even higher level of service and continue to grow our reputation as a leader in the supply chain solutions industry for clinical trials.”
As Oximio continues to expand its capabilities in East Africa, we remain focused on providing innovative solutions that meet the unique needs of the clinical trial industry. This new Customs Agent License strengthens our ability to offer a competitive edge in terms of both operational efficiency and cost-effectiveness.
Clients and prospective customers can be confident that with Oximio, their shipments will be handled with the utmost care, professionalism, and speed, as we manage the entire customs process in-house.
For more information on how our newly acquired Customs Agent License can benefit your shipments, please contact us. We’d be delighted to discuss your requirements.
Oximio Welcomes Bay Area Research Logistics, Canada to the Family, Expanding Global Reach and Service Capabilities
On 17 October, Oximio was delighted to welcome Bay Area Research Logistics (BARL), Canada to the Oximio family, a strategic move that strengthens Oximio’s global footprint and enhances its capabilities across the globe. Going forward, BARL will rebrand as Oximio BARL Canada.
With over 20 years’ experience providing clinical trial support services, this will bring significant benefits to both Oximio’s and BARL’s customers by combining Oximio’s extensive global supply chain expertise with BARL’s considerable experience in North American and global markets.
“This marks a significant milestone as we realise our strategy of continued growth and expansion into key markets” said Mykola Nikolaiev, Oximio’s Chief Executive Officer. “This exciting new addition to the business will create an organisation, even better placed to serve customers and compete on the global stage. We are excited about the expanded opportunities this will bring, and we look forward to working closely with our customers as we continue to innovate and deliver best-in-class supply chain solutions, tailored to customer requirements.”
“Joining Oximio marks an exciting new chapter for BARL,” said Kaitlin Guarasci, General Manager of Bay Area Research Logistics. “As the North American centre of Oximio, we will continue to provide trusted expertise in GMP packaging, storage, and distribution with the expanded access to Oximio’s global network.”
About BARL
Founded in 2007 and based in Hamilton, Ontario, Bay Area Research Logistics (BARL) is a Canadian leader in clinical trial packaging, labelling, temperature-controlled storage, and compliant distribution. BARL has supported hundreds of clinical trials for global biopharmaceutical companies and academic researchers.
Oximio Expands European Comparator Sourcing Capabilities with Ireland WDA Licence
We are delighted to announce a significant milestone in our global clinical trial support services: the accreditation of a Wholesale Distribution Authorisation (WDA) licence from the Health Products Regulatory Authority (HPRA) in Ireland. This development marks a key expansion of our procurement and comparator sourcing capabilities across Europe, enabling us to offer enhanced support to clinical trial sponsors, CROs, CDMOs and Academia throughout the region.
With over 20 years of industry experience, our team continues to build on a strong foundation of regulatory compliance, operational excellence, and global reach. The newly secured WDA licence complements our existing WDA accreditation from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, reinforcing our position as a trusted supply chain solutions partner for the healthcare industry.
Expanded Services to Meet European Procurement Needs
Our European comparator sourcing services for clinical trials now include:
- Tailored Comparator Drug Sourcing
Customised solutions to source high-quality, often hard-to-find comparator drugs with competitive pricing and efficient lead times. - Robust Supplier Network & Regulatory Assurance
Procurement through our network of approved suppliers ensures adherence to EU regulations and streamlined sourcing processes. - Expedited Processing Across Borders
With minimal “PO to Dispatch” timelines, we support urgent and multi-country study requirements. - Comprehensive Documentation
Full documentation including CoA, CoC, and MSDS is available, where stated, for most products within our portfolio.
A Collaborative Approach to Global Clinical Trials
At the heart of our service is a client-focused, collaborative approach. We work closely with trial sponsors and procurement teams to align comparator sourcing strategies with the specific needs of each study. Whether it’s negotiating bulk orders, navigating regulatory complexities, or managing supply chain logistics, our goal is to simplify procurement while maintaining the highest standards of quality and reliability.
This latest milestone supports our continued EU growth plans and reaffirms our mission to help bring innovative treatments to patients across Europe.
Contact us today to find out how our European sourcing capabilities can support your upcoming clinical trials. We’d be delighted to discuss your requirements.
Oximio Ukraine Recognised by Ministry of Health as a Critical Company to National Healthcare During Wartime
Oximio Ukraine is honoured to share that, as of January 2025, the Ministry of Health of Ukraine has officially recognized our role as critical to the national healthcare sector during wartime. This acknowledgment reflects Oximio Ukraine’s essential role in supporting and strengthening the country’s healthcare system in these challenging times.
To secure this recognition, we underwent a comprehensive evaluation process to demonstrate our vital contribution to Ukraine’s medical infrastructure.
This status enhances Oximio Ukraine’s business continuity capabilities during these challenging times. This recognition not only reinforces Oximio Ukraine’s local presence but also highlights the resilience of our entire global Group, as many global roles are based in Ukraine.
“We worked a lot to receive this status from the Ministry of Health,” said Olga Vizgalova, Managing Director of Oximio in Ukraine and Regional Director for Central Eastern Europe. “It is a reflection of the hard work and dedication of our entire team, whose commitment to excellence has enabled us to continue supporting Ukraine’s healthcare system and economy. This achievement strengthens our resolve to ensure the health and well-being of those who depend on us during these challenging times.”
We extend our heartfelt gratitude to all who contributed to this milestone. Their unwavering efforts make a meaningful impact within the company and in the broader healthcare landscape of Ukraine.
For further information on our clinical trial supply chain solutions in Ukraine, please view our website: https://oximio.com/network/ukraine/
Best Price and Shortest Lead Times for Avastin® from Ukraine and Georgia
According to Global Data oncology continues to dominate the clinical trial landscape in 2025. Avastin® (Bevacizumab) remains at the forefront in the treatment of a variety of cancers.
We are pleased to be able to offer Avastin® for clinical trials from Georgia and Ukraine at the most competitive prices with fast lead times. With our trusted supply chain and ability to provide Avastin® with Certificate of Analysis (CoA) and EU Equivalency, we can support your trial needs efficiently and cost-effectively. Available in 100mg and 400 mg vials, each with a minimum shelf life of 18 months.
If you’re planning a clinical trial and need Avastin®, please don’t hesitate to get in touch for a quotation. We’re here to help you secure the right supplies, exactly when you need them.
Contact us today. We’d be delighted to discuss your requirements.
